Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Frontiers in Oncology|December 6, 2021
Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung CancerAlessio Bruni, Vieri Scotti, Paolo Borghetti, et al.
Clinical Lung Cancer|August 24, 2022
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective StudyGiulia Mazzaschi, Fabiana Perrone, Roberta Minari, et al.
Molecular Cancer|January 14, 2025
Metabolically activated and highly polyfunctional intratumoral VISTA<sup>+</sup> regulatory B cells are associated with tumor recurrence in early-stage NSCLCDomenico Lo Tartaro, Beatrice Aramini, Valentina Masciale, et al.
JCO Precision Oncology|June 12, 2026
Liquid Biopsy Monitoring in <i>BRAF</i> V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020)Alessandro Leonetti, Monica Pluchino, Roberta Minari, et al.
The New England Journal of Medicine|May 29, 2026
First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion MutationsCaicun Zhou, Laurent Greillier, Geoffrey Liu, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2025
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)Francesco Facchinetti, Andrea Camerini, Chiara Bennati, et al.
Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2024
Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and databaseSujith Baliga, Ahmad K Abou-Foul, Pablo Parente, et al.
Tumori|May 4, 2026
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world studyAlessandro Leonetti, Vanessa Callegari, Fabiana Perrone, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexedAlessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.
Pageof 10